Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rohto Pharmaceutical Co's quarterly market cap
increased
from Sep. 2025 (円561,859 Mil) to Dec. 2025 (円593,833 Mil) but then
declined
from Dec. 2025 (円593,833 Mil) to Mar. 2026 (円544,008 Mil).
Rohto Pharmaceutical Co's annual market cap
declined
from Mar. 2024 (円676,204 Mil) to Mar. 2025 (円505,368 Mil) but then
increased
from Mar. 2025 (円505,368 Mil) to Mar. 2026 (円544,008 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Rohto Pharmaceutical Co's Enterprise Value for Today is 円541,997 Mil.
Rohto Pharmaceutical Co (TSE:4527) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Rohto Pharmaceutical Co Market Cap Related Terms
Rohto Pharmaceutical Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rohto Pharmaceutical Co Market Cap vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Rohto Pharmaceutical Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Rohto Pharmaceutical Co's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rohto Pharmaceutical Co (TSE:4527) has a Market Cap of 円550,223 Mil as of Jul. 21, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Rohto Pharmaceutical Co and its competitors. According to the industry distribution chart, Rohto Pharmaceutical Co ranks #127 out of 2048 companies in the Consumer Packaged Goods industry, placing it in the top 6.2%.
Is Rohto Pharmaceutical Co's Market Cap too high?
Rohto Pharmaceutical Co's current Market Cap is 円550,223 Mil. Based on the distribution chart, Rohto Pharmaceutical Co ranks #127 out of 2048 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Rohto Pharmaceutical Co has a GF Score™ of 92/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's Market Cap compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Rohto Pharmaceutical Co ranks #127 out of 2048 companies for Market Cap. This places Rohto Pharmaceutical Co in the top 6% of its industry — outperforming the majority of peers. The industry median Market Cap is 101.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Consumer Packaged Goods company?
The median Market Cap among Consumer Packaged Goods companies is 101.73, based on 2,048 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Rohto Pharmaceutical Co and its competitors. For the Consumer Packaged Goods industry, the median Market Cap is 101.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rohto Pharmaceutical Co's current Market Cap is 円550,223 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co (TSE:4527) is currently considered Significantly Undervalued. The stock's GF Value™ is 円3,477.35, compared to a current price of 円2,435.00 — trading 30% below its estimated fair value. The current Market Cap is 円550,223 Mil. Rohto Pharmaceutical Co's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Rohto Pharmaceutical Co (TSE:4527), the current Market Cap is 円550,223 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rohto Pharmaceutical Co (TSE:4527) Overvalued in 2026?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円2,435.00 is trading 30% below its estimated GF Value™ of 円3,477.35.
GuruFocus considers Rohto Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for TSE:4527:
Market Cap: 円550,223 Mil
GF Value™: 円3,477.35 vs. price of 円2,435.00 (30% below fair value)
No single metric tells the full story. See the TSE:4527 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
92GF Score
Get the complete analysis for TSE:4527
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4527 has been successfully added to your 
